蒋阳昆 陈黎 张红星 林海.阿德福韦酯联合胸腺肽?琢1治疗慢性乙型肝炎疗效分析[J].实用中西医结合临床,2010,(5):9-10 |
阿德福韦酯联合胸腺肽?琢1治疗慢性乙型肝炎疗效分析 |
|
|
DOI: |
中文关键词: 慢性乙型肝炎 阿德福韦酯 胸腺肽?琢1 |
英文关键词: Chronic hepatitis B Thymosin ?琢1 Adefovir |
基金项目: |
|
摘要点击次数: 621 |
全文下载次数: 322 |
中文摘要: |
目的:观察阿德福韦酯联合胸腺肽?琢1治疗慢性乙型肝炎(CHB)的疗效。方法:将86例HBeAg阳性的CHB患者随机分为联合治疗组和对照组各43例,联合治疗组同时使用阿德福韦酯与胸腺肽?琢1 24周,随后单用阿德福韦酯28周;对照组单用阿德福韦酯52周。观察两组患者治疗24周及52周时的HBeAg/HBeAb血清转换率、血清HBeAg转阴率、HBV-DNA转阴率及肝功能复常率。结果:治疗52周时联合治疗组HBeAg/HBeAb血清转换率、血清HBeAg转阴率、HBV-DNA转阴率及肝功能复常率明显高于对照组,两组比较有显著差异(P <0.05)。结论:阿德福韦酯联合胸腺肽?琢1治疗CHB的确具有协同抗HBV效应。 |
英文摘要: |
Objective:To observe the effect of adefovir and thymosin ?琢1 treatment of chronic hepatitis B (CHB).Methods:86 Patients with HBeAg-positive CHB were randomly divided into combined treatment group and control group,combined treatment group using both adefovir and thymosin ?琢1 24 weeks,followed by 28 weeks of adefovir dipivoxil alone;control group only 52 weeks with adefovir dipivoxil.2 groups were observed for 24 weeks and 52 weeks of HBeAg/HBeAb seroconversion rate,serum HBeAg negative rate,HBV-DNA negative rate and liver function recovery rate.Results:The combined treatment group after 52 weeks,HBeAg/HBeAb seroconversion rate,serum HBeAg negative rate,HBV-DNA negative rate and liver function recovery rate were significantly higher than contrel group,the two groups were significantly different(P <0.05).Conclusion:The treatment of adefovir combined with thymosin ?琢1 does have a synergistic anti-HBV effect. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |